Kevin R Fitzgerald

US Patent:

7605251, Oct 20, 2009

Filed:

May 10, 2007

Appl. No.:

11/746864

Inventors:

Pamela Tan - Kulmbach, DE
Birgit Bramlage - Kulmbach, DE
Kevin Fitzgerald - Brookline MA, US
Akin Akinc - Needham MA, US
Victor E. Kotelianski - Boston MA, US

Assignee:

Alnylam Pharmaceuticals, Inc. - Cambridge MA

International Classification:

A01N 43/04
A61K 31/70
C07H 21/02
C07H 21/04

US Classification:

536 245, 536 231, 536 243, 514 44

Abstract:

The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the proprotein convertase subtilisin kexin 9 (PCSK9) gene, comprising an antisense strand having a nucleotide sequence which is less than 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the PCSK9 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; and methods for treating diseases caused by PCSK9 gene expression by using the pharmaceutical composition.

US Patent:

7875711, Jan 25, 2011

Filed:

Apr 17, 2009

Appl. No.:

12/425811

Inventors:

Kevin Fitzgerald - Brookline MA, US
Gregory Hinkle - Plymouth MA, US

Assignee:

Alnylam Pharamaceuticals, Inc. - Cambridge MA

International Classification:

C07H 21/04

US Classification:

536 245, 536 241, 536 2431, 514 44

Abstract:

The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting X-Box Protein 1 (XBP-1), and methods of using the dsRNA to inhibit expression of XBP-1.

US Patent:

7956177, Jun 7, 2011

Filed:

Mar 23, 2007

Appl. No.:

12/294388

Inventors:

John Benson - West Roxbury MA, US
Birgit Bramlage - Kulmbach, DE
Kevin Fitzgerald - Brookline MA, US
Pamela Tan - Kulmbach, DE
Hans-Peter Vornlocher - Bayreuth, DE

Assignee:

Alnylam Pharmaceuticals, Inc. - Cambridge MA

International Classification:

C07H 21/04

US Classification:

536 245, 536 2431, 536 241, 435 6, 435325, 435375, 514 44

Abstract:

The invention relates to a double-stranded ribonucleic acid (dsRNA) for treating human papilloma virus (HPV) infection. The dsRNA comprises an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of an HPV Target gene selected from among HPV E1, HPV E6 and the human E6AP gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by HPV infection and the expression of the E6AP gene using the pharmaceutical composition; and methods for inhibiting the expression of the HPV Target genes in a cell.

US Patent:

8222222, Jul 17, 2012

Filed:

Sep 4, 2009

Appl. No.:

12/554231

Inventors:

Pamela Tan - Kulmbach, DE
Birgit Bramlage - Kulmbach, DE
Kevin Fitzgerald - Brookline MA, US
Akin Akinc - Needham MA, US
Victor E. Kotelianski - Boston MA, US

Assignee:

Alnylam Pharmaceuticals, Inc. - Cambridge MA

International Classification:

A01N 43/04
A61K 31/70
C07H 21/02
C07H 21/04

US Classification:

514 44, 536 231, 536 241, 536 243, 536 245

Abstract:

The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the PCSK9 gene (PCSK9 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the PCSK9 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by PCSK9 gene expression and the expression of the PCSK9 gene using the pharmaceutical composition; and methods for inhibiting expression of a PCSK9 gene in a cell.

US Patent:

8273869, Sep 25, 2012

Filed:

Jun 15, 2010

Appl. No.:

12/816207

Inventors:

Kevin Fitzgerald - Brookline MA, US
Gregory Hinkle - Plymouth MA, US
Akin Akinc - Needham MA, US
Stuart Milstein - Cambridge MA, US

Assignee:

Alnylam Pharmaceuticals, Inc. - Cambridge MA

International Classification:

C07H 21/04
C12N 15/85

US Classification:

536 245, 536 231, 435325

Abstract:

This invention relates to composition and methods using lipid formulated siRNA targeted to a PCSK9 gene.

US Patent:

8344126, Jan 1, 2013

Filed:

Dec 16, 2010

Appl. No.:

12/970189

Inventors:

Kevin Fitzgerald - Brookline MA, US
Gregory Hinkle - Plymouth MA, US

Assignee:

Alnylam Pharmaceuticals, Inc. - Cambridge MA

International Classification:

C07H 21/04

US Classification:

536 245, 536 2431, 536 241, 514 44, 435 6, 435325, 435375

Abstract:

The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting X-Box Protein 1 (XBP-1), and methods of using the dsRNA to inhibit expression of XBP-1.

US Patent:

8598139, Dec 3, 2013

Filed:

Aug 7, 2012

Appl. No.:

13/568898

Inventors:

Kevin Fitzgerald - Brookline MA, US
Gregory Hinkle - Plymouth MA, US
Akin Akinc - Needham MA, US
Stuart Milstein - Cambridge MA, US

Assignee:

Alnylam Pharmaceuticals, Inc. - Cambridge MA

International Classification:

A61K 48/00
C12N 15/85
C07H 21/04

US Classification:

514 44, 536 231, 536 245, 435325

Abstract:

This invention relates to composition and methods using lipid formulated siRNA targeted to a PCSK9 gene.

US Patent:

20060234973, Oct 19, 2006

Filed:

Apr 12, 2006

Appl. No.:

11/402608

Inventors:

Kevin Fitzgerald - Brookline MA, US
Donald Jackson - Lawrenceville NJ, US
Qi Guo - Newtown PA, US

International Classification:

A61K 48/00
C12N 15/09

US Classification:

514044000, 435455000

Abstract:

The present invention concerns methods and reagents useful in modulating transcription factor gene expression in a variety of applications, including methods of use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), and doublestranded RNA (dsRNA) molecules capable of mediating RNA interference (RNAi) against E2F1 gene expression, useful in the treatment of cell cycle disorders, inflammatory conditions, reproductive disorders, cancers and any other condition that responds to modulation of E2F1 expression and/or activity.